Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectors

Journal of Virology

Volumn 83, Issue 8, 2009, Pages 3450-3462

  Robinson, Michael ^a   Li, Betty ^a   Ge, Ying ^a   Ko, Derek ^a   Yendluri, Satya ^a   Harding, Thomas ^a   VanRoey, Melinda ^a   Spindler, Katherine R ^b   Jooss, Karin ^a  

^a CELL GENESYS INC   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS 5 E2F VECTOR; ADENOVIRUS VECTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MOUSE ARMED ONCOLYTIC ADENOVIRUS DLE102; MOUSE ARMED ONCOLYTIC ADENOVIRUS PME301; ONCOLYTIC ADENOVIRUS; UNCLASSIFIED DRUG; ONCOLYTIC VIRUS;

ADENOVIRUS 5; ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER TUMOR; BREAST TUMOR; COLON CARCINOMA; COLON TUMOR; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; EMBRYO; FEMALE; GENE EXPRESSION; HOST RESISTANCE; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOMODULATION; IMMUNOTHERAPY; LUNG TUMOR; MOUSE; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; SARCOMA; SINGLE DRUG DOSE; TRANSGENE; TUMOR CELL; TUMOR CELL LINE; TUMOR MODEL; VIROTHERAPY; VIRUS REPLICATION; ADENOVIRUS; ANIMAL; BIOSYNTHESIS; GENE THERAPY; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; METHODOLOGY; NEOPLASM; PATHOLOGY; VIROLOGY;

ADENOVIRIDAE; ANIMALIA; HUMAN ADENOVIRUS; MURINAE; MURINE ADENOVIRUS 1;

ADENOVIRIDAE; ANIMALS; GENE THERAPY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; MICE; MODELS, ANIMAL; NEOPLASMS; ONCOLYTIC VIRUSES;

EID: 64049109524     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02561-08     Document Type: Article

References (67)

1. Alemany, R., C. Balague, and D. T. Curiel. 2000. Replicative adenoviruses for cancer therapy. Nat. Biotechnol. 18:723-727. (Pubitemid 30460686)
2. Ball, A. O., M. E. Williams, and K. R. Spindler. 1988. Identification of mouse adenovirus type 1 early region 1: DNA sequence and a conserved transactivating function. J. Virol. 62:3947-3957.
3. Beard, C. W., and K. R. Spindler. 1996. Analysis of early region 3 mutants of mouse adenovirus type 1. J. Virol. 70:5867-5874. (Pubitemid 26266798)
4. Beard, C. W., and K. R. Spindler. 1995. Characterization of an 11K protein produced by early region 3 of mouse adenovirus type 1. Virology 208:457-466.
5. Biederer, C., S. Ries, C. H. Brandts, and F. McCormick. 2002. Replication-selective viruses for cancer therapy. J. Mol. Med. 80:163-175. (Pubitemid 34230636)
6. Blanke, C., C. Clark, E. R. Broun, G. Tricot, I. Cunningham, K. Cornetta, A. Hedderman, and R. Hromas. 1995. Evolving pathogens in allogeneic bone marrow transplantation: increased fatal adenoviral infections. Am. J. Med. 99:326-328.
7. Bristol, J. A., M. Zhu, H. Ji, M. Mina, Y. Xie, L. Clarke, S. Forry-Schaudies, and D. L. Ennist. 2003. In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF. Mol. Ther. 7:755-764.
8. Carrigan, D. R. 1997. Adenovirus infections in immunocompromised patients. Am. J. Med. 102:71-74. (Pubitemid 127695951)
9. Cauthen, A., and K. Spindler. 1999. Construction of mouse adenovirus type 1 mutants, p. 85-103. In W. S. M. Wold (ed.), Adenovirus methods and protocols, vol.21. Humana Press, Inc., Totowa, NJ.
10. Cauthen, A. N., and K. R. Spindler. 1999. Novel expression of mouse adenovirus type 1 early region 3 gp11K at late times after infection. Virology 259:119-128.
11. Charles, P. C., J. D. Guida, C. F. Brosnan, and M. S. Horwitz. 1998. Mouse adenovirus type-1 replication is restricted to vascular endothelium in the CNS of susceptible strains of mice. Virology 245:216-228.
12. Chartier, C., E. Degryse, M. Gantzer, A. Dieterle, A. Pavirani, and M. Mehtali. 1996. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J. Virol. 70:4805-4810. (Pubitemid 26187479)
13. Dechecchi, M. C., P. Melotti, A. Bonizzato, M. Santacatterina, M. Chilosi, and G. Cabrini. 2001. Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J. Virol. 75:8772-8780. (Pubitemid 32768981)
14. Dechecchi, M. C., A. Tamanini, A. Bonizzato, and G. Cabrini. 2000. Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology 268:382-390.
15. Eggerding, F. A., and W. C. Pierce. 1986. Molecular biology of adenovirus type 2 semipermissive infections. I. Viral growth and expression of viral replicative functions during restricted adenovirus infection. Virology 148:97-113.
16. Fang, J., S. Yi, A. Simmons, G. H. Tu, M. Nguyen, T. C. Harding, M. VanRoey, and K. Jooss. 2007. An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo. Mol. Ther. 15:1153-1159. (Pubitemid 46813618)
17. Fang, L., and K. R. Spindler. 2005. E1A-CR3 interaction-dependent and -independent functions of mSur2 in viral replication of early region 1A mutants of mouse adenovirus type 1. J. Virol. 79:3267-3276. (Pubitemid 40327916)
18. Flomenberg, P., J. Babbitt, W. R. Drobyski, R. C. Ash, D. R. Carrigan, G. V. Sedmak, T. McAuliffe, B. Camitta, M. M. Horowitz, N. Bunin, et al. 1994. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J. Infect. Dis. 169:775-781.
19. Fox, J. P., C. D. Brandt, F. E. Wassermann, C. E. Hall, I. Spigland, A. Kogon, and L. R. Elveback. 1969. The virus watch program: a continuing surveillance of viral infections in metropolitan New York families. VI. Observations of adenovirus infections: virus excretion patterns, antibody response, efficiency of surveillance, patterns of infections, and relation to illness. Am. J. Epidemiol. 89:25-50.
20. Freytag, S. O., B. Movsas, I. Aref, H. Stricker, J. Peabody, J. Pegg, Y. Zhang, K. N. Barton, S. L. Brown, M. Lu, A. Savera, and J. H. Kim. 2007. Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol. Ther. 15:1016-1023. (Pubitemid 46621661)
21. Fueyo, J., C. Gomez-Manzano, R. Alemany, P. S. Lee, T. J. McDonnell, P. Mitlianga, Y. X. Shi, V. A. Levin, W. K. Yung, and A. P. Kyritsis. 2000. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19:2-12.
22. Ginsberg, H. S., L. L. Moldawer, P. B. Sehgal, M. Redington, P. L. Kilian, R. M. Chanock, and G. A. Prince. 1991. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc. Natl. Acad. Sci. USA 88:1651-1655.
23. Guida, J. D., G. Fejer, L. A. Pirofski, C. F. Brosnan, and M. S. Horwitz. 1995. Mouse adenovirus type 1 causes a fatal hemorrhagic encephalomyelitis in adult C57BL/6 but not BALB/c mice. J. Virol. 69:7674-7681.
24. Halldén, G., R. Hill, Y. Wang, A. Anand, T. C. Liu, N. R. Lemoine, J. Francis, L. Hawkins, and D. Kirn. 2003. Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy. Mol. Ther. 8:412-424. (Pubitemid 37161463)
25. Hartley, J. W., and W. P. Rowe. 1960. A new mouse virus apparently related to the adenovirus group. Virology 11:645-647.
26. Hawkins, L. K., and T. Hermiston. 2001. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the E3B region. Gene Ther. 8:1142-1148.
27. Hawkins, L. K., L. Johnson, M. Bauzon, J. A. Nye, D. Castro, G. A. Kitzes, M. D. Young, J. K. Holt, P. Trown, and T. W. Hermiston. 2001. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19 K region. Gene Ther. 8:1123-1131.
28. He, T. C., S. Zhou, L. T. da Costa, J. Yu, K. W. Kinzler, and B. Vogelstein. 1998. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA 95:2509-2514.
29. Heise, C., T. Hermiston, L. Johnson, G. Brooks, A. Sampson-Johannes, A. Williams, L. Hawkins, and D. Kirn. 2000. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. 6:1134-1139.
30. Jin, F., P. J. Kretschmer, and T. W. Hermiston. 2005. Identification of novel insertion sites in the Ad5 genome that utilize the Ad splicing machinery for therapeutic gene expression. Mol. Ther. 12:1052-1063. (Pubitemid 41723039)
31. Johnson, L., A. Shen, L. Boyle, J. Kunich, K. Pandey, M. Lemmon, T. Hermiston, M. Giedlin, F. McCormick, and A. Fattaey. 2002. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 1:325-337.
32. Kajon, A. E., C. C. Brown, and K. R. Spindler. 1998. Distribution of mouse adenovirus type 1 in intraperitoneally and intranasally infected adult outbred mice. J. Virol. 72:1219-1223. (Pubitemid 28116906)
33. Ko, D., L. Hawkins, and D. C. Yu. 2005. Development of transcriptionally regulated oncolytic adenoviruses. Oncogene 24:7763-7774.
34. Kojaoghlanian, T., P. Flomenberg, and M. S. Horwitz. 2003. The impact of adenovirus infection on the immunocompromised host. Rev. Med. Virol. 13:155-171. (Pubitemid 36566085)
35. Kring, S. C., C. S. King, and K. R. Spindler. 1995. Susceptibility and signs associated with mouse adenovirus type 1 infection of adult outbred Swiss mice. J. Virol. 69:8084-8088.
36. Kring, S. C., and K. R. Spindler. 1996. Lack of effect of mouse adenovirus type 1 infection on cell surface expression of major histocompatibility complex class I antigens. J. Virol. 70:5495-5502. (Pubitemid 26240724)
37. Larsen, S. H., and D. Nathans. 1977. Mouse adenovirus: growth of plaque-purified FL virus in cell lines and characterization of viral DNA. Virology 82:182-195.
38. Le, H. N., N. C. Lee, K. Tsung, and J. A. Norton. 2001. Pre-existing tumor-sensitized T cells are essential for eradication of established tumors by IL-12 and cyclophosphamide plus IL-12. J. Immunol. 167:6765-6772. (Pubitemid 33144166)
39. Lenaerts, L., D. Daelemans, N. Geukens, E. De Clercq, and L. Naesens. 2006. Mouse adenovirus type 1 attachment is not mediated by the coxsackie-adenovirus receptor. FEBS Lett. 580:3937-3942. (Pubitemid 43946887)
40. Lenaerts, L., E. Verbeken, E. De Clercq, and L. Naesens. 2005. Mouse adenovirus type 1 infection in SCID mice: an experimental model for antiviral therapy of systemic adenovirus infections. Antimicrob. Agents Chemother. 49:4689-4699.
41. Li, B., A. S. Lalani, T. C. Harding, B. Luan, K. Koprivnikar, G. Huan Tu, R. Prell, M. J. VanRoey, A. D. Simmons, and K. Jooss. 2006. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin. Cancer Res. 12:6808-6816.
42. Li, B., J. Lin, M. Vanroey, M. Jure-Kunkel, and K. Jooss. 2007. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb. Clin. Immunol. 125:76-87. (Pubitemid 47374542)
43. Lin, J. M., B. Li, E. Rimmer, M. VanRoey, and K. Jooss. 2008. Enhancement of the anti-tumor efficacy of a GM-CSF-secreting tumor cell immunotherapy in preclinical models by cytosine arabinoside. Exp. Hematol. 36:319-328.
44. Moore, M. L., C. C. Brown, and K. R. Spindler. 2003. T cells cause acute immunopathology and are required for long-term survival in mouse adenovirus type 1-induced encephalomyelitis. J. Virol. 77:10060-10070. (Pubitemid 37122087)
45. Moore, M. L., E. L. McKissic, C. C. Brown, J. E. Wilkinson, and K. R. Spindler. 2004. Fatal disseminated mouse adenovirus type 1 infection in mice lacking B cells or Bruton's tyrosine kinase. J. Virol. 78:5584-5590. (Pubitemid 38661645)
46. Nemunaitis, J. J., J. M. McKiernan, D. L. Lamm, M. V. Meng, J. C. Arseneau, J. Stephenson, J. M. Burke, J. Aimi, and D. J. Maslyar. 2008. Phase 1 study of multi-dose administration of intravesical CG0070 in patients with non-muscle invasive bladder cancer (NMIBC). Mol. Ther. 16:S256.
47. Post, L. E. 2002. Selectively replicating adenoviruses for cancer therapy: an update on clinical development. Curr. Opin. Investig. Drugs 3:1768-1772.
48. Raman, S., T. H. Hsu, S. L. Ashley, and K. R. Spindler. 28 January 2009. Integrin and heparan sulfate usage as receptors for mouse adenovirus type 1. J. Virol. doi:10.1128/JVI.02368-08.
49. Ramesh, N., Y. Ge, D. L. Ennist, M. Zhu, M. Mina, S. Ganesh, P. S. Reddy, and D. C. Yu. 2006. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor-armed oncolytic adenovirus for the treatment of bladder cancer. Clin. Cancer Res. 12:305-313.
50. Reddy, P. S., S. Ganesh, and D. C. Yu. 2006. Enhanced gene transfer and oncolysis of head and neck cancer and melanoma cells by fiber chimeric oncolytic adenoviruses. Clin. Cancer Res. 12:2869-2878.
51. Robinson, M., Y. Ge, D. Ko, S. Yendluri, G. Laflamme, L. Hawkins, and K. Jooss. 2008. Comparison of the E3 and L3 regions for arming oncolytic adenoviruses to achieve a high level of tumor-specific transgene expression. Cancer Gene Ther. 15:9-17. (Pubitemid 350261295)
52. Rowe, W. P., and J. W. Hartley. 1962. A general review of the adenoviruses. Ann. N. Y. Acad. Sci. 101:466-474.
53. Sarkar, D., Z. Z. Su, and P. B. Fisher. 2006. Unique conditionally replication competent bipartite adenoviruses-cancer terminator viruses (CTV): efficacious reagents for cancer gene therapy. Cell Cycle 5:1531-1536.
54. Schaack, J. 2005. Induction and inhibition of innate inflammatory responses by adenovirus early region proteins. Viral Immunol. 18:79-88. (Pubitemid 40586447)
55. Silverstein, G., and W. A. Strohl. 1986. Restricted replication of adenovirus type 2 in mouse Balb/3T3 cells. Arch. Virol. 87:241-264. (Pubitemid 16180329)
56. Simmons, A. D., M. Moskalenko, J. Creson, J. Fang, S. Yi, M. J. VanRoey, J. P. Allison, and K. Jooss. 2008. Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity. Cancer Immunol. Immunother. 57:1263-1270.
57. Smith, K., C. C. Brown, and K. R. Spindler. 1998. The role of mouse adenovirus type 1 early region 1A in acute and persistent infections in mice. J. Virol. 72:5699-5706. (Pubitemid 28283354)
58. Smith, K., B. Ying, A. O. Ball, C. W. Beard, and K. R. Spindler. 1996. Interaction of mouse adenovirus type 1 early region 1A protein with cellular proteins pRb and p107. Virology 224:184-197.
59. Spindler, K. R., M. L. Moore, and A. N. Cauthen. 2007. Mouse adenovirus, A. Smith (ed.), The mouse in biomedical research, 2nd ed., vol.II. Academic Press, Inc., New York, NY.
60. Thomas, M. A., J. F. Spencer, M. C. La Regina, D. Dhar, A. E. Tollefson, K. Toth, and W. S. Wold. 2006. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res. 66:1270-1276. (Pubitemid 43259903)
61. Toth, K., J. F. Spencer, A. E. Tollefson, M. Kuppuswamy, K. Doronin, D. L. Lichtenstein, M. C. La Regina, G. A. Prince, and W. S. Wold. 2005. Cotton rat tumor model for the evaluation of oncolytic adenoviruses. Hum. Gene Ther. 16:139-146. (Pubitemid 40250340)
62. van der Veen, J., and A. Mes. 1973. Experimental infection with mouse adenovirus in adult mice. Arch. Gesamte Virusforsch. 42:235-241.
63. Warrens, A. N., M. D. Jones, and R. I. Lechler. 1997. Splicing by overlap extension by PCR using asymmetric amplification: an improved technique for the generation of hybrid proteins of immunological interest. Gene 186: 29-35.
64. Weinberg, J. B., G. S. Stempfle, J. E. Wilkinson, J. G. Younger, and K. R. Spindler. 2005. Acute respiratory infection with mouse adenovirus type 1. Virology 340:245-254.
65. 5 promote adenovirus internalization but not virus attachment. Cell 73:309-319.
66. Wold, W. S., and M. S. Horwitz. 2007. Adenoviruses, p. 2395-2436. In D. M. Knipe and P. M. Howley (ed.), Fields virologyt, vol.2. Lippincott Williams & Wilkins, Philadelphia, PA.
67. Ying, B., K. Smith, and K. R. Spindler. 1998. Mouse adenovirus type 1 early region 1A is dispensable for growth in cultured fibroblasts. J. Virol. 72:6325-6331. (Pubitemid 28323942)